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COMPARATIVE STUDY OF DIFFERENT MODALITIES OF TREATMENT 
IN NEOVASCULAR GLAUCOMA  
ABSTRACT 
AIM :  To analyze about comparative effect of Trabeculectomy with Mitomycin  
C/ Trabeculectomy with Ologen implant/ Glaucoma drainage device surgery in 
25 cases of Neovascular glaucoma. To find out best method, control of 
intraocular pressure, visual outcome, post operative complications. To find out 
the etiological factors, mode of presentation and associated systemic conditions. 
METHODS : In this pilot study, 25 patients of neovascular glaucoma were 
selected , evaluated and divided into 3 groups.Group1: 10 patients were treated 
with Trabeculectomy with Mitomycin C. Group 2: 10 patients were treated with 
Trabeculectomy with Ologen implant. Group 3 : 5 patients were treated with 
drainage device surgery.All patients were re- examined first post operative day 
and then end of first week, 6 week and 12week. The control of intraocular 
pressure , visual outcome , post operative complications were assessed.  Effect 
of different methods of treatment compared and best method of treatment was 
analysed. 
RESULTS:The major aetiological factors causing Neovascular glaucoma are 
proliferative diabetic retinopathy, central retinal vein occlusion, recurrent 
anterior uveitis.The mean age of presentation was 59.04 years with male 
preponderance.Neovascular glaucoma secondary to Central Retinal Vein 
Occlusion presented earlier than proliferation diabetic retinopathy which was 
presented relatively later.At most cases had corneal and iris involvement with 
new vessels extending into the angle with or without synechial angle 
closure.The mean pre treatment intra ocular pressure was 45.76mmHg. among 
the three modalities of treatment maximum mean reduction of IOP in the first 
week was seen in group III (drainage implant surgery). But at the end of 12 
weeks of follow up all three groups showed statistically significant reduction of 
mean IOP. There is no significant gross difference between these groups at the 
end of 12 weeks. Group I -Trabeculectomy with Mitomycin - c showed more 
complication compare to other 2 groups, shallow anterior chamber and bleb 
related complications more common in group I.Group II- Trabeculectomy with 
ologen implant showed minimal complications.In Group III- drainage device 
surgery patients had complications like hyphaema, tube contact with cornea and 
pain intra operative bleeding is more common in neo vascular glaucoma 
patients. 
CONCLUSION:.At the end of 12 weeks of follow up all three groups showed 
statistically significant reduction of mean IOP. There is no significant gross 
difference between these groups at the end of 12 weeks.In severely 
compromised eyes with Neovascular glaucoma, the main advantage of Keiki 
Metha Valve implantation is pain relief and avoidance of enucleation in 
addition to a significant reduction in intra ocular pressure. If the patients would 
have presented earlier and managed appropriately, this much dreaded 
complication of painful Neovascular glaucoma could be avoided earlier 
KEYWORDS : Neovascularisation, Trabeculectomy , Mitomycin – C , Ologen , 
Drainage device  
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PART I
1INTRODUCTION
DEFINITION
Glaucoma may be defined as state of  raised IOP which is  not  compatible with
normal health and function of that particular eye (Duke elder).
          Glaucoma is a chronic progressive optic neuropathy caused by a group of
ocular pathology which lead to characteristic changes in the structure of the
optic nerve head, functional visual changes and characteristic corresponding
field changes. The most common risk factor is raised intra ocular pressure.
CLASSIFICATION
            Clinical classification of glaucoma based on evidence based categories .
1. Glaucoma suspects
2. POAG
3. PACG
4. Glaucoma with secondary ocular pathology
PRIMARY
            Bilateral genetically determined condition not associated with known
ocular or systemic disorders that account for the reduction in aqueous outflow.
2SECONDARY
            Usually unilateral and based on the presence of optic neuropathy, in the
presence of a secondary ocular pathological process. These processes may
include neovascularisation, uveitis, trauma, lens related glaucoma, pigment
dispersion, pseudo-exfoliation, etc.
NEOVASCULAR GLAUCOMA
           Secondary type of glaucoma is caused by a fibro vascular membrane that
develops on surface of iris and the angle. Neovascularglaucoma never occurs as
a primary condition but it is always associated with other abnormalities, mostly
ischemia.
OTHER NOMENCLATURE
Hemorrhagic Glaucoma: Referring to hyphaema that is present in some cases
Thrombotic Glaucoma: Underlying vascular thrombotic etiology
Congestive Glaucoma: describing acute nature of this condition.
Rubeotic glaucoma:
3HISTORICAL REVIEW
 In 1906 Coats described the histologic findings of new vessels on the iris in
CRVO. 1928, Salus described it in Diabetics. Kurz correlative his clinical
observation of fine new vessels in the angle with histological findings of
connective tissue along the vessels.
Since the glaucoma is caused by new vessels rather than inconsistently present
intraocular bleeding, Weis and Shaffer proposed the term ‘Neo vascular
glaucoma’. Ashton in 1957 proposed that the pre requesitefor
neovascularisation was hypoxic metabolism. The fibro vascular membrane
across the angle causes a secondary open angle glaucoma and subsequently
synechial angle closure, a secondary angle closure glaucoma results. Duke Elder
stated that the resulted thrombosis is a disastrous condition and only practical
treatment is enucleation. However  over the past decade, studies have been
made in our understanding of and ability to treat neovascular glaucoma.
4THEORIES OF NEOVASCULO GENESIS
Mechanism is not fully understood. Although following theories have been
proposed1.
Retinal hypoxia
             Most of the conditions associated with rubeosisiridis involve
diminished perfusion of retina. So retinal hypoxia is one of the factor in the
formation of new vessels on the iris, angle, retina, and optic nervehead. Ex:
CRVO, diabetic retinopathy.
Angiogenesis Factors
VEGF explains ocular neo vascularisation can occur in areas remote from the
site of retinal capillary non-perfusion. Muller’s cells are the primary source of
VEGF in retinal ischemia conditions. VEGF 165 is the most abundant form.
This mediates retinal ischemia associated ocular neovascularisation by
neutralizing anti VEGF antibodies, thus preventing iris neovascularisation.
Chronic Dilatation of  Ocular Vessels
             Dilatation of vessels is the stimulus leading to growth of new vessels in
response to hypoxia.
Vasoinhibitory Factors
           Vitreous and lens are sources of vasoinhibitory factors, which could
explain why vitrectomy or lensectomyincreases the  risk for rubeosisiridis in
diabetic retinopathy RPE cells  release inhibitors of neovascularisation.
5CLINICAL COURSE
Pre rubeosis stage
Predisposing factors such as diabetic retinopathy/CRVO. Treatment may be
induced before rubeosis is detected.
Preglaucoma stage: rubeosisiridis
Characterised by normal IOP unless pre- existing chronic open angle glaucoma
is present.
SLE - dilated tufts of pre- existing capillaries and fine randomly oriented
vessels on surface of the iris near the pupillary margin. Most commonly first
seen in peri pupillary region. In CRVO and diabetic retinopathy it may be first
seen in the angle.
 Histology - New vessels are characterised by having thin fenestrated walls,
arranged in irregular pattern.
Open  angle glaucoma stage
 All rubeosis does not lead to NVG, they may resolve spontaneously.Incidence
of NVG in diabetic patients with rubeosisiridis is 13-41%. In vascular occlusive
disease this occurs typically after 8-15 months. This called as 90day glaucoma.
On SLE- AC reaction, sometimes hyphaema is seen.Gonioscopy- angle open
and neo vascularisationintense . IOP–elevated.
HPE- fibro vascular membrane covers the angle , anterior surface of iris and
even extend into posterior surface
STAGES OF NEOVASCULAR GLAUCOMA
A. RUBEOSIS ATAGE
B. OPEN ANGLE STAGE
C. ANGLE CLOSURE STAGE
6Angle closure glaucoma stage
SLE- Iris stroma smooth, glistening and flattened.Ectropion uvea is frequently
seen.Gonioscopy – angle- PAS formation with eventualy total synechiaepresent.
DIFFERENTIAL DIAGNOSIS
Angle closure glaucoma- acute stage.
Glaucoma associated with anterior uveitis- Eyes with uveitis do not have
new vessels but dilatation of normal vessels may be found.
Fuchs heterochromiciridocyclitis- New vessels in angle with filiform
haemorrhages on paracentesis with heterochromia present.
D/D Must include other causes of iris distortion and PAS such as ICE syndrome
and old trauma.
DIFFERENCE BETWEEN NEW VESSELS AND NORMAL IRIS
VESSELS
Normal iris vessels
 Never crosses the scleral spur,located in the stroma,typical radial arrangement.
New vessels
               Crosses scleral spur, located on surface with irregular arrangement, do
not follow radial pattern.
7MICROSCOPICALLY
New vessels-thin walled with irregular endothelium, lack of endothelial tight
junction and lacks pericytes present. It arises from normal arterioles in the iris
and ciliary body and leak fluorescein.
PHASES OF NEOVASCULARISATION OF IRIS AND NVG
1. Early iris neovascularisation
       Tiny tufts of new vessels appear at the pupillary margin, difficult to
detect .
2. Moderate iris neovascularisation
       New vessels extend towards the angle and sometimes joining the
dilated vessel at the collerate.
3. Advanced iris neovascularisation with angle neovascularisation
        New vessels reach the angle and join the circumferential ciliary body
artery. New vessels emanate from this artery and cross over the sclera
spur into the trabecular meshwork where arborisation occurs. A fibro
vascular membrane accompanying these vessels, all though invisible on
gonioscopy mayblock enough of trabecular meshwork to cross the
secondary form of open angle glaucoma.
4. Advanced NVG with synechial angle closure with contraction of
fibrovascular membrane
This results in PAS and synechial angle closure.
Radial traction along the surface of iris results in ectropion uvea.
8AETIO PATHOGENESIS OF NVG
STAGES OF ANGIOGENESIS
1.     Increased endothelial cell permeability – VEGF
2.     Breakdown of basement membrane and ECM-FGF
3.     Endothelial buds through basement membrane and ECM-
    VEGF, PGP
4.     Endothelial cell migration VEGF, FGF
5.     Endothelial cell branching and lumen formation – FGF
MICHALION first postulated - existence of vasoformative factors X
which control the normal development of new vessels during
embryogenesis. WISE – states retinal capillary lumen obstruction resulted
in hypoxia of the retinal cells, which produces a vasopromotive factor.
ASHTON – formulated that vasoformative factor which diffuses
anteriorly to cause iris angiogenesis.
A vast number of factors have been postulated as being initiators,
messengers  or  mediators  of  angiogenesis  such  as,  biogenic  amines  -
histamine, Ach, serotonin, PGE1, activatedleucocytes, activated
macrophages and angiogenin. There is a fine balance between factors
which stimulates and inhibit blood vessel formation which gets altered in
hypoxia. Neo vascularisation begins as endothelial budding from
capillaries of minor arterial arcadeat the pupillary margin.
BRANCH RETINAL VEIN OCCLUSION
BRANCH RETINAL VEIN OCCLUSION – FFA
CENTRAL RETINAL VEIN OCCLUSION
RHEGMATOGENOUS RETINAL DETACHMENT
9Fibrovascular membrane is a proliferative myofibroblast.This leads to the
development of ectropion uvea, formation of PAS -  synechial angle
closure.
1. CRVO
Accounts 28% of rubeosisiridis cases. It is either most common or
second most common cause of NVG. Optic disc cupping, elevated
IOP, HT, DM, Male are the risk factors2.
2. DIABETIC (PDR)
        One of the most common cause of NVG accounting for 1/3 of
case. Incidence of rubeosisiridis after pars planavitrectomy– 25 to
42% whereas NVG 10 to23%. It occurs mainly in aphakic patients
than phakic. Retinal detachment after vitrectomy, cataract surgery also
increase incidence of NVG in diabetic patients3.
3. POST CATARACT EXTRACTION NVG
         Surgical procedures such as cataract extraction with vitrectomy
in DR increase the risk of development of NVG. It is greater in ICCE
than ECCE due to easier passage of angiogenesis factor from the
posterior to anterior segment due to loss of diffusion barrier. Adequate
PRP should be done in any DM patients with early PDR before
cataract extraction is performed.
CHRONIC UVEITIS
PROLIFERATIVE DIABETIC RETINOPATHY
PROLIFERATIVE DIABETIC RETINOPATHY - FFA
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4. EXTRA OCULAR VASCULAR DISORDERS
Carotid artery obstructive diseases is probably third most common
cause of NVG incidence 13%. Carotid cavernous fistula also cause
decrease ocular perfusion leads onto NVG.
5. CRAO
7-15% with CRAO will develop NVG. But some have concomitant
carotid artery occlusive disease. Although PRP may have some effect in
reducing the incidence of NVG, it is not as such as much as effective in
CRVO or DM.
6.     INTRAOCULAR TUMORS
Ellett noted the association between untreated malignant melanoma
and NVG. Occurrence of iris neovascularisation correlates with
increased tumour size, tumour necrosis and extent of RD, and duration
of tumour. Children with opaque media and iris neovascularisation or
NVG one must consider occult retinoblastoma.
7. UVEITIS
One of the most common cause of iris neovascularisation and
NVG.Incidence 11%. It can result in inflammatory membrane that
stretches across the angle, the contraction of which results in
secondary angle closure glaucoma. Fuchs heterochromiccyclitis
vessels are thin walled, fragile, increased tendency to bleed easily,
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either spontaneously or as a consequence of sudden lowering of IOP
or by gonioscopy.
8. MISCELLANEOUS
Irradiation, sickle cell retinopathy , coats disease….etc
CLINICAL FEATURES
Symptoms :
Pain/ watering / redness / photophobia and defective vision.
Signs:
Conjunctiva – CCC(+)
Cornea – hazy cornea, thickening, oedema, vascularisation, bullae,
Iris – Neovascularisation, loss of pattern, atrophy. Iris neovascularisation at
pupillary margin is the earliest sign of  NVG.
AC – Flare/ cells / Hyphaema .
Angle – New vessels / Fibrovascular membrane / PAS.
IOP- stony hard. Tension around 40-80mm Hg.
FUNDUS – findings of DR / CRVO /CRAO / Tumours / RD.
VISION-  usually Hand movements to NO PL.
GRADING OF NEOVASCULARISATION
ANGLE NEOVASCULARISATION
ANGLE NEOVASCULARISATION IN ALL QUADRANTS
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CLASSIFICATION AND GRADING OF NEOVASCULARISATION
               Grading based on evaluation of pupillary margin, mid stromal iris, iris
base and angle .
 A – at pupillary margin B – mid stromal iris, C –  mid stromal iris and angle,
and D indicate PAS. Numbers grade 1,2,3,4 indicates number of quadrants
involved. IOP greater than 21 mm Hg is denoted by adding a + sign. Diabetic
iridopathy is classified as grade 4.
GRADE 0: No diabetic iridopathy
GRADE 1:Non proliferative diabetic iridopathy ( dialated pupillary and stromal
capillaries with short lasting fluorescence)
GRADE 2  :   Proliferative diabetic iridopathy – new vessel at pupillary margin
and or stroma( filling rapidly with the dye and leaking equally, promptly and
diffusely).
GRADE 3  :Neovascular glaucoma
INVESTIGATIONS
FFA – to evaluate new vessels and large areas of capillary non perfusion
B SCAN ULTRASOUND – Revealing occult malignancy presenting as NVG
and  shown  to  be  considered  for  all  cases  in  which  the  cause  of  anterior
neovascularisation is unclear and fundus cannot be visualised.
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GONIOSCOPY– To evaluate for new vessels and fibrovascular membrane in
the angle.
TONOMETRY – To asses IOP.
SLIT LAMP WITH 90D – To evaluate posterior segment
VISUAL FIELDS( if possible)
PROPHYLAXIS ( CHANDLER )
             Key stone for prevention of NVG is retinal ablation in which by means
of photocoagulation or cryotherapy, retinal tissue is destroyed leading to
inhibition and even reverse the new vessel proliferation in anterior segment .If
media opacities present -retinal cryoablation is the alternate approach- effective
in reducing anterior segment vasoproliferation.
GONIO PHOTOCOAGULATION
Meticulous application of small laser burns to the trunk of new vessels as they
cross the ciliary body and sclera spur – blanching of fine vascular network.It
interupts a critical tissue response to the angiogenic stimulus while retinal
photocoagulation appears to reduce the stimulus itself4.
PAN- RETINAL PHOTOCOAGULATION
Is effective in prevention of rubeosis due to CRVO and PDR.
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             Prophylactic methods are only performed for ischemic CRVO only in
the event that anterior segment neovascularisation develops. Central retinal vein
occlusion study concluded that PRP is the effective treatment for
neovascularisation of anterior segment causedby ischemic CRVO.Even after
standard course of PRP, careful monitoring of iris and angle so that further
retinal ablation can be done if new vessels develop.
TREATMENT
EARLY STAGE
1. Treatment of  the underlying cause5
2. MEDICAL TREATMENT : Based on aqueous suppressants such as
Carbonic anhydrase inhibitors, beta blockers, apraclonidine
3. Supplementation with Anti- inflammatory therapy – steroids
4. Cycloplegics – 1% atropine to reduce the pain and ciliary spasm
5. Pan Retinal Photocoagulation
6. Endophotocoagulation
7. Pan Retinal Cryotherapy
8. Goniophotocoagulation
PANRETINAL PHOTOCOAGULATION (PRP)
             PRP introduced by Meyer Schwickerath in 1955 to treat diabetic
retinopathy.  Mechanism - panretinal photocoagulation must eliminate the
TREATMENT ALGORITHYM OF NVG
Neovascularisation of angle /Iris
NVA/NVI
Normal IOP High IOP
Useful Vision No useful vision
No Pain Pain
Topical Steriods
Cycloplegia
Cyclodestruction
Alcohol Injection
Evisceration
Enucleation
Duration of IOP
Elevation and Extent of
Disc cupping
Medical Therapy
IOP Still high
Glaucoma surgery
Aqueous tube shunts
Trabeculectomy with antimetabolites
Diode laser cyclodestruction
Type of diseases
causing NVA / NVI
Inflammatory
Disorder
Retinal Ischemic
Disorder
Steroids
Cycloplegia
Media
Clear
Media
Not Clear
Follow IOP
Panretinal Photo
Coagulation (PRP)
Indirect PRP
Diode Retinopexy
Retinal
Cryoablation
Vitrectomy /
Endolaser
Complete
(1200-1600
Laser spots)
Not Complete
Follow up Gonioscopy, Slit lamp
Examination, IOP and Fundus
Examination
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source and /or antagonize the effect of the angiogenesis factor. The
effectiveness of various lasers depend on the amount of retina treated than the
type of laser employed. Argon laser selectively damages the outer higher
oxygen consuming layer namely photoreceptor- retinal pigment epithelium
complex. Alteration of retinal pigment epithelium layer in photocoagulation
results in increase release of inhibitor of vascular proliferation and
neovascularisation. A total of 1200- 1600 burns, 500 microns in size should be
applied randomly over the peripheral retina.
When adequate panretinal photocoagulation is performed early in the course of
iris neovascularisation there is ample documentation that there is regression of
iris vessels in CRVO, diabetics and even in carotid occlusive disease6.
Endophotocoagulation: Intraoperatively, endophotocoagulation with argon
laser can be just as effective as standard photocoagulation especially during
vitrectomy .
Panretinal Cryotherapy: In cases where the dioptric media is too hazy to
allow adequate photocoagulation, there is a role for panretinal cryotherapy.  A
360 degree peritomy is done and four recti isolated. A 2.5mm retinal cryoprobe
with first  row of application just  anterior  to the equator .  Three spots  between
each rectus muscle and two additional rows placed posteriorly. -70 degree C
application for 5-10 secs used. Potential complications  include traction and
exudative retinal detachment and vitreous haemorrhage. This procedure
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produces more inflammation and blood retinal breakdown than
photocoagulation. Anterior retinal cryoablation is also mode of management
which is considered a useful preliminary procedure prior to seton surgery.
Laser Goniophotocoagulation : It is indicated in patients with active and
progressive angle neovascularisation despite previous panretinal
photocoagulation . Laser goniophotocoagulation is best viewed as an adjunct to
panretinal photocoagulation . New vessels are treated as they cross the scleral
spur, the ciliary body and base of the iris. The setting include 100-200 microns
spot size, 200-600 mV power of 0.2 sec. Duration. Transient iritis and
hyphaema may occur.
THERAPEUTIC-LATE STAGE : Late stage of neovascular glaucoma is
when synechial angle closure has occurred.
Panretinal Photocoagulation: Though synechial angle closure cannot be
reversed, panretinal  photocoagulation or parental cryotherapy should still be
performed to eliminate the stimulus for new vessel formation. At least 3-4
weeks should elapse between panretinal photocoagulation and filtering surgery.
Medical Therapy : Medications that decrease aqueous production such as
topical beta blockers and carbonic anhydrase inhibitors are beneficial but do not
lower intra ocular pressure to a normal range in the face of a closed angle .
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Osmotic agents can be used intermittently to clear the cornea. The most
important medications are 1% atropine and topical steroids.
Conventional Filtering Surgery: Patients with neovascular glaucoma tend to
experience early failure of filtering surgery with closure of fistula and scarring
of bleb within first few post operative weeks. The presence of active
neovascularisation leads to late bleb failure through conjunctival scarring at the
filtration site. Intra operative and post operative haemorrhage are major
complications.
Before the advent of panretinal photocoagulation, electocautery iridotmy non
penetrating eye diatheramy were performed to control bleeding during surgery.
Whatever the surgical procedure, pre-operative panretinal photocoagulation
should be performed whenever possible7. After adequate panretinal
photocoagulation, topical atrophine and steroids, a full thickness procedure such
as trephine or guarded procedure such as trabeculectomy may be performed.
The results are same regardless of the type of surgery. A preplaced paracentes is
allows  slow decompression of a firm eye, irrigation of blood from the anterior
chamber if necessary and reformation of anterior chamber and filtration bleb at
the end of the procedure. Allen showed a success of 67% success being defined
as an intra ocular pressure less than 25 mm Hg. Post operatively the filtration
bleb tends to be limited in size, less succulent and often has a characteristic ring
of conjunctival and episcleral vessels which delineate base of bleb.
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Pars planaTrabeculectomy : This can only be performed in an aphakic eye
that has undergone a pars plana vitrectomy. The operation is similar to a
conventional trabeculectomy but the scleral flap is fashioned over the pars
plana. A piece of deep scleral tissue and ciliary body are excised together with
any residual vitreous. The risk of haemorrhage is small as the engorged vessels
in the anterior segment remain undisturbed. This procedure is usually performed
for neovascular glaucoma following pars planavitrectomy in a diabetic eye.
Pharmacological modulation of filtering surgery
5-Fluorouracil and mitromycin - C are used as pharmacological modulators in
neovascular glaucoma. It is used in neovascular glaucoma cases for its
prevention of impending bleb failure, and to reduce the vascularisation of bleb.
It increases the success rate (60% to 90%) in eye that are at risk of failure8.
5- Fluorouracil
                  5- Fluorouracil is a pyrimidine analog. Inhibits the enzyme
thymidylatesynthetase thus impending DNA synthesis9.Commercially available
– 1 ampoule- 500mg in 5ml or 250mg in 2.5ml. Intra operative dose – 50mg/ml.
Dose : after surgery 5mg is injected twice daily subconjunctivally for 1 week
and then 5 mg once daily in the 2nd week.
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Mitomycin C
Mitomycin C is an alkylating ,antitumour antibiotic that interrupts DNA
replication. Isolated from Streptomyces caespitosus. It inhibits fibroblast
proliferation and subsequent scar formation.  Dose : Sponge soaked in 0.2
mg/ml. Duration 2-4 min. Available in powder form 1 vial= 2mg or 10 mg.
Indications:
1. Young patients - < 40 yrs
2. Secondary glaucoma- uveitic, NVG, aphakic, post keratoplasty.
3. Failed trabeculectomy.
4. High preoperative IOP > 35 to 40mmhg at presentation.
Complications:
1. Cataract
2.  avascular bleb
3.  bleb leak
4. Bleb dyesthesia- cystic overhanging or elevated bleb
5. Hypotony- hypotonusmaculopathy, choroidaldetatchment, shallow
anterior chamber.
6.  Risk of endophthalmitis.
Mitomycin C has a greater effect on post operative pressure reduction than 5
FU11.
MITOMYCIN
OLOGEN
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OLOGEN IMPLANT:
                  It ia a biodegradable (90-180 days)  collagen implant-porous matrix
of cross linked atelocollagen and glycosaminoglycons.Its available in
6mm×2mm, 10mm×10mm×2mm. Mechanism: modulation of wound healing.
Reorganisation of newly formed fibroblast and adjacent extracellular
subtances.Acts as a spacer between conjunctiva and sclera maintaining the
patency of subconjunctival space. It is placed directly over the scleral flap and it
influences the healing process.
Advantages: Increases the success rate by reducing the fibrosis12. It maintains
functional bleb with normal conjunctiva. Minimal rejection – as there is no
immune response. Ready to use.Easy to handle.Post surgical infection is
minimal as the surface immunity of conjunctiva is not altered.
VALVE IMPLANT SURGERY:
                 One of the major problems in neovascularglaucoma is failure of
filtration bleb through conjunctival- Tenon’s capsule – episcleral scarring.
Setons are synthetic devices that are used in glaucoma surgery to maintain a
patent drainage fistula13.
Aims :1.To prevent closure of fistula. 2. To preventfibrosis of
subconjunctivaltenon’s tissue bleb site. 3. Provide a shunt for aqueous from the
anterior chamber to the suprachoroidal space and sub tenon space14.
DIFFERENT SHAPES OF OLOGEN
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 Various materials including horsehair, silk, tantalum, platinum,
supramid, gelatine, silicon have been used as setons.
Types :    A.   Translimbal aqueous drainage from anterior chamber to anterior
chamber to anterior subconjunctival space. Eg. Drupin Denver Valve
(Standard).
               B.  Translimbal aqueous drainage from anterior chamber  into a
posterior subtenon reservoir. Eg.Molteno implant, Schocket Implant ( anterior
chamber tube shunt  to encircling band) ACTSEB, Joseph Valve, Long Krupin
Valve.
               C.   Aqueous drainage from anterior chamber to supra-choroidal space
through a cyclodialysis cleft. Eg. Modified Schocket Implant.
MOLTENO IMPLANT:
Molteno was the first investigator to clinically developed a translimbal implant
connected to posterior located collecting reservoir.
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Implant :  It  consists  of  a  silicone tube with an outer  diameter  of  0.63mm and
inner diameter of 0.33 mm that connects to the upper surface of a thin acrylic
plate 13mm in diameter which acts as a collecting reservoir. The plate’s surface
is concave and fits snugly on to the sclera surface between two rectus muscles.
Edge of plate has a thickened rim 0.7mm in height that is perforated to permit
suturing of the plate to sclera.
Mechanism : The plate promotes the formation of a vascular connective tissue
that encapsulates the implant with formation of an aqueous filled cavity.
Advantages : 1. Production of posterior exit of tube from fibrotic obstruction .
2. An increase surface area for drainage of aqueous . 3. Distention of sub tenon
space by the collecting reservoir, promoting formation of a large uniocular bleb
in a free communication with anterior chamber. 4. Reduced probability  of
implant eroding through the conjunctiva owing to its sub tenon location. 5.
More effective in controlling intra ocular pressure.
Types :
SINGLE PLATE MOLTENO IMPLANT( 13mm diameter adult and 9mm
diameter paediatric)
DOUBLE PLATE MOLETENO IMPLANT( 13mm diameter adult and 9mm
diameter paediatric).
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KEIKI MEHTA VALVE
Introduced by Keiki Mehta.Very simple and effective device.3 parts – tube,
membrane valve, button. All made of medical grade silicon.
Important features:
1. BP or Body Pressure valve- when pressure of fluid in eye more
than pressure of body tissues , valve open and allow fluid. It
regulates flow.
2. Peaks on button- keeping conjunctiva and tenon’s away from
button to facilitate distribution of fluid around. Fluid can pass
beyond button also, because there is no limiting ridge around.
Effectively it has large absorption area of fluid to get absorbed
back.
3. Soft and flexible button with rough upper surface – soft part –
easy to implant , rough surface- create large surface and prevent
sticking.
Three sizes- regular, small, large.
Procedure : first of all take out the tag inserted in to the valve then flush the
shunt with normal saline with 27 gauge needle. No air bubble should be left
inside the tubing and patency of shunt is also checked by flushing the tube.
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Steps of surgery:  A fornix based flap of conjunctiva and tenon is raised in
supranasal  or  supronasal  or  supertemporal  quadrant.  Some  surgeons  prefer  a
limbus based flap with or without creating a sclera pouch. After ceuterization,
plate is tucked into sub tenon space posteriorly and sutured to sclera, with its
anterior border 9- 10mm posterior to the limbus. A rectangular half thickness 4×
3mm sclera flap is dissected. The long silicone tube is cut bevel upto permit its
extension 2-3mm into the anterior chamber. A 21 gauge needle is introduced
into the anterior chamber parallel to this plane. Tube is directed through the
needle track into anterior chamber. It is secured to the sclera by sutures. The
sclera flap is closed and conjunctiva and tenon sutured.
COMPLICATIONS:
INTRAOPERATIVE: Bleeding, button holes, sclera perforation too posterior
entrance into the anterior chamber, misdirection of tube in anterior chamber,
flattened anterior chamber, suprarchoroidal haemorrhage15.
POSTOPERATIVE: Hyphaema, flattened anterior chamber, prolonged
hypotony, tube tip block by iris blood or vitreous, contract of tube with cornea
iris or lens, erosion of tube through sclera and conjunctiva late failure from
excessive fibrosis.
MALTINO IMPLANT
KEIKI MEHTA VALVE
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ANTI-VEGF AGENTS
Many case reports have attempted to ascertain the value of intraocular anti-
VEGF therapy with bevacizumab as an adjunctive treatment of iris
neovascularization associated with glaucoma . These reports in patients with
either diabetes or central retinal vein occlusion and associated neovascular
glaucoma involved injecting 1.25-mg bevacizumab into the vitreous cavity16 or
1.0- to 1.25-mg bevacizumab in the anterior chamber before or concomitant
with panretinal photocoagulation.
Virtually all treated eyes had significant regression of anterior segment
neovascularization within 48 hours, many with a concomitant reduction in IOP.
The injected medication was reported to be safe and well tolerated17. The effect
of bevacizumab lasted for a number of weeks, and thereafter, new vessel
formation was noted to resume in some eyes. Hence, it is important to proceed
with panretinal photocoagulation as soon as practical to help prevent recurrent
neovascularization. Intraocular injections of bevacizumab can be repeated, but
how often eyes can be reinjected remains to be determined.
 END STAGE NEOVASCULAR GLAUCOMA:
When there is total synechial angle closure and no useful vision, control of pain
becomes the primary aim.
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Medical: Combination of 1% atropine and topical steroids provide enough
symptomatic relief.
Cyclodestructive  procedures: Cyclodestructive procedures aim to decrease
the ciliary process secretion of aqueous humour resulting in decrease intraocular
pressure. This  is achieved  by selective destruction of the epithelial layers of
the ciliary process or  interruption of the blood supply to the ciliary body.
Various modalities include cyclodiathermy, cycloelectrolsis, cycloanaemisation,
cyclocryotherapy, trans sclera or  trans pupillary laser cycloablation, trans sclera
high intensity ultrasound, laser endophotocoagulationcycloablation and excision
of ciliary body.
Cyclodiathermy: involves diathermy application 1.5mm to 3.5mm from the
limbus. It is less beneficial, more destructive and long term success is quite
limited.
Cycloelectrolysis: introduced by Berens is a technique to create tissue
decompensation using sodium hydroxide with galvanic energy to produce
chemical dissolution of the ciliary process
Cycloanaemisation: involved disinsertion of horizontal rectus muscles and
placement of eight to ten puncture sites at the insertion site to coagulate the long
posterior ciliary arteries.
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Transpupillary Laser Cycloablation: utilizes argon laser energy applied
through a gonioprism to the visible ciliary processes, blanching and pigment
disruption being the desired tissue response. Limitation include the needs for
adequate visualization of ciliary processes and that anterior tip of ciliary process
is visualised, leaving a functional portion of untreated posterior ciliary process.
Complications include haemorrhage and iritis. Setting includes 50-200 microns
spot size, 600-1000 mw power for 0.1- 0.2 sec duration.
Neodymium YAG Transcleral Cyclophotocoagulation: uses 1064mm light
which penetrates intact sclera and causes controlled destruction of ciliary
processes. Complications include hyphaema, conjunctival oedema, corneal
oedema, gas bubbles in anterior chamber, hypotony and vitreous haemorrhage.
Setting includes 70 microns spot size, 0.5-4.2 power, 32-40 applications for a
duration of 20m sec.
Laser Endophotocoagulation Cycloablation: involves applying argon laser
energy to the ciliary body through an endolaser probe after cataract and vitreous
surgery and allows to quantitateciliary ablation.
Transcleral Ultrasound : involves application of a focussed high intensity
ultrasonic beam that produces localised heating within the sclera and underlying
ciliary body. Complications include scleral thinning, chronic inflammation,
corneal changes, post operative pressure rise and phthisis bulbi.
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CYCLOCRYOTHERAPY :Cyclocryotherapy was introduced by Bietti in
1950. De Roetth established Cyclocrotherapy as an effective form of treatment
in advanced glaucoma.
The mechanism involves freezing of the ciliary processes which results in a
marked decrease in the stromal vascularity and extensive disruption of
pigmented and non pigmentedciliary epithelium, there by reducing the aqueous
tumour production18.
Cyclocryotherapy is indicated when medical therapy does not provide relief in
end stage neovascular glaucoma. Cyclocryotherapy is contraindicated in
neovascular glaucoma secondary to post inflammatory etiology.
The relief of pain is one of the major benefits of cyclocryotherapy and may
occur despite persistent corneal oedema and high intra ocular pressure. GRANT
attributed the beneficial effect to freezing of corneal nerves.
On Cyclocryotherapy, the area immediately under the probe is frozen and from
this point, the freeze expands in all directions. The temperature of the ice ball is
not  the  same at  all  points.  If  the  temperature  at  the  sclera  is  -80  degree  C the
average temperature at the ciliary body is -10 degree C because of the heat
supplied by blood flow in ciliary body vessels.
Following retrobulbar anaesthesia, cryoprobe 3.5 – 4mm diameter is applied to
the conjunctiva, with the nearest edge 2.5mm from limbus at a temperature of -
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80 degree C. The probe is applied over 180 degree of the globe with
approximately six equidistant points for a duration of 1 minute. Soluble
dexamethasone is injected subconjunctivallyin the area of the freeze. Topical
steroids and topical 1% atropine are applied along with analgesics.
The full effect of cyclocryotherapy on intra ocular pressure becomes apparent
after 4 weeks of treatment.
Complications include hyphaema, iridocyclitis, corneal dellen, synechiae
formation, vitreous haemorrhage, macular oedema, choroidal detachment and
phthisis bulbi.
RECENT ADVANCES
Verteporfin (Visudyne) is a light-activated drug used in photodynamic therapy
(PDT).  Once verteporfin is activated by light in the presence of oxygen, highly
reactive, short-lived reactive oxygen radicals are generated.  Light activation of
verteporfin results in local damage to neovascular endothelium, resulting in
vessel occlusion. So photodynamic therapy can be used safely and effectively in
the early phases of Neovascular glaucoma to achieve angle neovascularisation
obliteration and reduction of IOP.
PART II
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COMPARATIVE STUDY OF DIFFERENT MODALITIES OF
TREATMENT IN NEOVASCULAR GLAUCOMA
AIM OF THE STUDY
To analyze about comparative effect of Trabeculectomy with Mitomycin  C/
Trabeculectomy with Ologen implant/ Glaucoma drainage device surgery in 25
cases of Neovascular glaucoma examined in Regional Institute of
Ophthalmology, Government Ophthalmic Hospital, Chennai.
PRIMARY OBJECTIVE
To find out best method of treatment in this comparative study.
To assess the control of intraocular pressure,visual outcome, post operative
complications in Neovascular glaucoma patients who are under different
methods of treatment.
SECONDARY OBJECTIVE
To find out the etiological factors,mode of presentation and associated systemic
conditions.
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REASON FOR THE STUDY
Though a considerable number of Neovascular glaucoma cases attend various
institutions, much importance was not given to analyse these cases because of
poor functional recovery.There has been a considerable change in the line of
management of Neovascular glaucoma after understanding the
aetiopathogenesis in the past decade. Hence this study was suggested to find out
the above aim .
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MATIERIALS AND METHOD
This prospective study was conducted on 25  Patients attending  our Glaucoma
clinic with  Neovascular glaucoma were evaluated in terms of  detailed history
regarding onset, duration , presenting symptoms, ocular and systemic
predisposing factors like diabetes , hypertension , vascular diseases and chronic
uveitis was recorded .
A thorough evaluation of patients which included general and ocular
examination was performed. Anterior segment examination by slit lamp
biomicroscopy, tonometry, gonioscopy,visual acuity recording, fundus
examination and in selected cases fundus flourescein angiography and
ultrasound examination was done. For suspected cases of diabetes and patients
with family history of diabetes – fasting and post prandial blood sugar, urine for
albumin and sugar was done.
INCLUSION CRITERIA:
a] All patients with neovascular glaucoma of varied etiology.
b] Patients who accepted treatment .
c] Patients with vision more than perception of light, raised intraocular pressure,
neovascularisation of iris, angle and elsewhere in fundus.
d] Patients with a follow up period of at least twelve weeks
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EXCLUSION CRITERIA:
a]Patients with primary glaucoma.
b] Patients with dilated vessels alone in iris without evidence of new vessels .
c] Patients with other type of secondary glaucoma.
ANTERIOR SEGMENT EXAMINATION
Anterior segment was examined for the following details.
Cornea- keratic precipitates, bullous keratopathy, oedema, haziness and opacity,
vascularisation.
Anterior chamber- hyphaema, flare, cells.
Iris – neovascularisation including grading, pattern ,atrophic patches, nodular
thickening.
Pupil – reaction,posteriorsnechiae,ectropionuveae, inflammatory membrane.
Lens – cataract ,pseudophakia , aphakia.
TONOMETRY
Intraocular pressure was measured with Schiotz tonometer with standard
weights, Non contact tonometry, Goldmannapplanation tonometer whenever
possible.
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GONIOSCOPY
Angle assessment was done with Goldmann single mirror indirect goniolens and
the following features were noted- grading of the angle by Shaffer’s grading,
presence and extent of neovascularisation and peripheral anterior
synechiae.Grading of neovascularisation was done based on the extent of iris
neovascularisation,angle neovasularisation, presence of peripheral anterior
synechiae and the number of quadrants involved.
POSTERIOR SEGMENT EXAMINATION
Posterior  segment  examination  was  done  in  both  eyes  with  direct,  indirect
ophthalmoscope, slit lamp biomicroscopy with 90D lens and goldmann 3 mirror
fundus contact lens whenever the clarity of media permitted .
VISUAL FIELD
Visual field charting was not possible in the affected eyes due to poor visual
acuity. Central and peripheral chatting were done with Bjerrum screen and
Automatedprimetry in the fellow eye.
ULTRASOUND EXAMINATION
B scan were done in selected patients were posterior segment could not be
visualised and assessed for presence of vitreous haemorrhage and retinal
detachment .
35
SYSTEMIC EVALUATION
This included recording of blood pressure, fasting and post-prandial blood
sugar, complete blood count, erythrocyte sedimentation rate and urine analysis
for sugar and albumin.
MANAGEMENT
Medical treatment was started for all cases which included 0.5% timolol twice
daily, oral acetazolamide 250 mg QID, oral glycerol 30ml twice daily(if not
diabetic), topical steroids four times daily, 1% atropine (whenever indicated).
25 patients are divided into 3 groups for each method of treatment .
 10  patients  were  treated  with  Trabeculectomy  with  Mitomycin  C.  It   is   an
alkylating,  antitumour  antibiotic  that  interrupts   DNA  replication  .  Dose  –
sponge soaked in 0.2mg/ml. Duration 2- 4 min. Available in powder form 1 vial
=2mg or 10 mg.
      10 patients were treated with Trabeculectomy with Ologen implant. It is a
biodegradable collagen implant porous matrix of cross linked atelocollagen and
glycosaminoglycons. Its available in 6mm×2mm, 10mm×10mm×2mm.
Mechanism: modulation of wound healing. Reorganisation of newly formed
fibroblast and adjacent extracellular subtances.Acts as a spacer between
conjunctiva and sclera maintaining the patency of subconjunctival space. It is
placed directly over the scleral flap and it influences the healing process.
      5 patients were treated withGlaucoma drainage device implantsurgery(Keiki
Mehta valve – Regular size). It provides shunt for aqueous from anterior
chamber to suprachoroidal space and subtenon space.
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FOLLOW UP PROCEDURES/ VISITS
All patients were re- examined first post operative day and then end of first
week, 6 week and 12week. At each visit anterior segment examination by slit
lamp biomicroscopy, Tonometry ,Gonioscopy, visual acuity recording, fundus
examination were done. The control of intraocular pressure , visual outcome ,
post operative complications were assessed.  Effect of different methods of
treatment compared and best method of treatment was found out.
STATISTICAL ANALYSIS
 All data were entered into the computer for the suitable statistical analysis. The
statistical analysis were carried out by statistical package SPSSPC
(STATISTICAL PACKAGE FOR SOCIAL SCIENCE).Paired and independent
t- test was applied for the continuous data. One way analysis of variance was
applied to find the significance between more than two groups .p< 0.05 was
considered to be significant.
ANALYSIS AND DISCUSSION
4906 Glaucoma cases were detected in glaucoma clinic, Regional Institute of
Ophthalmology,Government Ophthalmic Hospital, Chennai during the period
June 2011- June 2013and 25 cases of Neovascular glaucoma were selected for
this study.
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AGE INCIDENCE
  Age Groups Frequency  %
 41-50            2  8
 51-60           15  60
61 and above            8        32
     Mean age of presentation was 59.04 years. (Range 41-70 years, S.D = 5.72).
The mean age in diabetic Neovascular glaucoma was 58.66 years, Neovascular
glaucoma secondary to vein occlusion 61.83 years, Neovascular glaucoma
secondary to chronic recurrent uveitis 56 years.
     In total the incidence of Neovascular glaucoma was maximum between 51-
60 years.
      The diabetic Neovascular glaucoma presented at a earlier age compared to
Neovascular glaucoma secondary to vein occlusion.
SEX INCIDENCE
Sex Frequency            %
         Male           18  72
       Female    7           28
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The male to female ratio was 2.5:1 which shows that there was male
preponderance of neovascular glaucoma in this study.
AGE AND SEX DISTRIBUTION
LATERALITY
 Eye Frequency            %
     RIGHT EYE            16           64
      LEFT  EYE              9           36
The right eye was affected more (64%) than the left (36%).
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CAUSES OF GLAUCOMA
 Causes  Frequency           %
Proliferative Diabetic
Retinopathy
           12          48
CRVO             6          24
Recurrent anterior uveitis             2            8
Hypertension             1            4
others             4          16
PDR accounted for 48%, CRVO 24%, recurrent anterior uveitis 8%,
hypertension 4%, others 16%.. Other causes included post traumatic (2), post-
surgical (2) .Nowadays, post traumatic cause emerges significance in
developing Neovascular glaucoma.
CAUSES OF GLAUCOMA
PDR
CRVO
RECURRENT ANTERIOR
UVEITIS
HYPERTENSION
OTHERS
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                   DURATION OF GLAUCOMA ILLNESS
Duration PDR CRVO Uveitis HT Others Total
0-6
months
    - 5(20) 1(4%)     - 2 (8%) 8(32%)
7-12
months
5(20%) 1(4%) 1(4%) 1(4%) 1(4%) 9(36%)
> 1 year 7 (28%)     -     -     - 1(4%) 8(32%)
Most of the patients secondary to CRVO presented within 6 months which may
be due to rapid development of neovascularisation process. 28% of diabetes
presented after a year. This relatively late presentation may be due to less
virulent nature of new vessels ( TheGlaucomas Bruce Shields).
                                 ANTERIOR SEGMENT
Cornea
Features Frequency %
Mild haziness 3 12
Oedema 18 72
Bullous keratopathy 1 4
Vascularisation 1 4
Keratic precipitates 2 8
Opacification 3 12
Iris pigments 3 12
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Corneal decompensation was found in most of the cases reflecting the advanced
stage of presentation and high intraocular pressure. Keratic precipitates were
seen in group where Neovascular glaucoma occured secondary to uveitis.
Iris
Feature Frequency  %
Atrophic patches 5 20
Loss of pattern 8 32
Neovascularisation 25 100
Iris bombe 1 4
100% of patients had iris neovascularisation.
                GRADING OF NEOVASCULARISATION
Grade Diabetes
No (%)
CRVO
No (%)
Uveitis
No (%)
HT
No(%)
Others
No(%)
A4 1(4) - - - -
B4 3(12) 1(4) 1(4) - 2(8)
C2 - 1(4) - - -
C3 4(16) 1(4) 1(4) 1(4) 1(4)
D3 - - - - 1(4)
D4 - 3(12) - - -
IRIS NEOVASCULARISATION
IRIS NEOVASCULARISATION – 7’O CLOCK POSITION
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Out of  the 25 patients only 21 patients grading was done. 4 patients grading
was not possible due to advanced corneal decompensation. 13 patients had
grade C and D. This reflects the advanced stage of presentation of Neovascular
glaucoma.
Lens
Feature Diabetes
No(%)
CRVO
No(%)
Uveitis
No(%)
HT
No(%)
Others
No(%)
Mild
haziness
1(4)     -     -     -     -
IMC 6(24) 4(16) 1(4) 1(4) 2(8)
MC     - 1(4) 1(4)     -     -
Aphakia     -     -     -      - 1(4)
PCIOL 4(16) 1(4)     -      - 1(4)
ACIOL 1(4)     -     -      -     -
Out of the 25 patients, 8(32%) were previously operated for cataract.
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POSTERIOR SEGMENT EXAMINATION
Feature Frequency %
Clear view 1 4
Hazy view 17 68
No view 7 28
Diabetic retinopathy 8 32
CRVO 4 16
Hypertensive retinopathy 4 16
Out  of   12  patients  of  diabetes  4  patients  had  no  view  of  fundus  due  to
cataractous changes and corneal oedema. 8 patients had evidence of
proliferative diabetic retinopathy in both eyes. 2 patients had previous history
pan retinal photocoagulation treatment in the fellow eye.
Out of 6 CRVO patients, 1 patient had no view of fundus due to mature
cataract, 3 patients had both eyes hypertensive retinopathy changes, 1 patient
had BE diabetic retinopathy changes, 1 patient had fellow eye retinal
detachment with aphakia, 1 patient had CRVO coexisting with CRAO.
Out of 2 uveitic patients, 1 patient had BE- fundus- no view due to mature
cataract. He is a known case of Hansen’s disease. Anti leprotic treatment course
completed 10 years back. Other patient had BE fundus- hazy view.
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In 2post surgical and 2 post traumatic cases fundus - hazy view noted. In
1patient Bscan – shows evidence of vitreous haemorrhage.
VISUAL ACUITY
Vision  PDR
No (%)
CRVO
No (%)
Uveitis
No (%)
HT
No(%)
Others
No(%)
Total
No(%)
PL 2(8) 3(12)     -     - 4(16) 9(36)
HM 4(16) 1(4) 1(4) 1(4)     - 7(28)
CFCF 1(4)     - 1(4)     -     - 2(8)
>CFCF 5(20) 2(8)     -     -     - 7(28)
Most of the patients having poor vision due to corneal decompensation ,
glaucoma progression and primary fundus pathology.
PRE TREATMENT INTRA OCULAR PRESSURE
IOP(mmHg) PDR
No %
CRVO
No %
Uveitis
No %
HT
No %
Others
No %
Total
No%
31-40 5(20) 2(8)     -     - 1(4) 8(32)
41-50 4(16) 2(8) 2(8)     - 2(8) 10(40)
51-60 1(4) 1(4)     - 1(4) 1(4) 4(16)
61 & above 2(8) 1(4)     -     -     - 3(12)
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Mean pre treatment IOP was 45.76mmHg(Range 34to 69 S.D.10.70).
Mean  IOP  in  diabetic  group   –  44.53mmHg,  Mean  IOP  in  CRVO  group  -
46.92mmHg and Mean IOP in uveitis group - 46.15mmHg.
MANAGEMENT
Management  PDR CRVO Uveitis  HT Others  Total
Trabeculectomy
with MMC
3 2 1 1 3 10(40%)
Trabeculectomy
with Ologen
8 2     -    -     - 10(40%)
Drainage
implant surgery
1 2 1    - 1 5(20%)
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        There was no statistically significant difference between the three
management modalities with respect to varied aetiology. Similarly there was no
statistically significant difference of age, sex and laterality with respect to the
three treatment groups.
PRE TREATMENT INTRAOCULAR PRESSURE
IOP
(mmHg)
GroupITrabeculectomy
with MMC
GroupIITrabeculectomy
with Ologen
GroupIIIDrainage
implant surgery
31-40 2 4 2
41-50 5 4 1
51-60 3 1 1
61&
above
    - 1 1
MANAGEMENT
TRABECULECTOMY WITH MMC
TRABECULECTOMY WITH
OLOGEN
DRAINAGE DEVICE SURGERY
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The mean pre treatment IOP in Group I was 47.36 mmHg (S.D 8.89 S.E 2.82)
in GroupII was 43.7mmHg (S.D 10.88 S.E 3.43) and in Group III was
46.72mmHg (S.D 14.98 S.E 6.83).There was no statistically significant
difference in the mean IOP between the 3 groups.
POST TREATMENT INTRA OCULAR PRESSURE
Group  Pre- treatment            Mean IOP ± S.D.(mmHg)
1 week 6 week 12 week
I 47.36±8.89 20.7±11.47 16.58±7.64 16.93±7.43
II 43.7±10.88 26.8±6.87 20.7±7.24 17.4±4.22
III 46.72±14.98 17.4±5.36 17.14±6.9 20.34±5.23
Unpaired T-test  was undergone. Probability of Group I<0.0001,   Group
II<0.0006 and  Group III< 0.0033.There was statistically significant reduction
of  IOP in all  three groups in the follow up period.  In aetiological  groups also
significant reduction of IOP waspresent( PDR < 0.0001 , CRVO <0.0001).
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REDUCTION OF IOP IN GROUP I (TRABECULECTOMY WITH
MITOMYCIN - C)
IOP(mmHg) Frequency  Mean Standard
deviation
Standard
error
Pretreatment 10 47.36 8.89 2.82
12 weeks 10 16.93 7.43 2.34
This analysis showed that there was significant reduction in the IOP in Group I
(trab with MMC) at the end of 12 weeks P(<0.0001)19,23.
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REDUCTION OF IOP IN GROUP II (TRABECULECOMY WITH
OLOGEN)
IOP(mmHg) Frequency  Mean Standard
deviation
Standard
error
Pre treatment 10 43.7 10.88 3.43
12 weeks 10 17.4 4.22 1.33
This analysis showed that there was significant reduction in the IOP in Group II
at the end of 12 weeks P (<0.0006)20.
REDUCTION OF IOP IN GROUP III (GLAUCOMA DRAINAGE
DEVICE SURGERY)
IOP(mmHg) Frequency Mean Standard
deviation
Standard
error
Pre treatment 5 46.72 14.98 6.83
12 weeks 5 20.34 5.23 3.45
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This analysis  showed that  there was significant  reduction in the IOP in Group
III at the end of 12 weeks. P(<0.0033)21.
Mean IOP reduction in Group I was 28.3,Group II was 26.3, whereas in Group
III was 26.38.
DIFFERENCE IN REDUCTION OF MEAN IOP (%)
Group Frequency
            Mean IOP ±S.D
S.E
1 week 6 week 12 week
I 10 24.96±17.58 29.08±14.13 28.73±13.27 4.23
II 10 16.7±6.73 24±8.85 26.3±10.54 3.32
III 5 29.32±18.51 29.58±19.24 26.38±17.84 8.04
Maximum mean reduction of IOP in 1 week seen in group II.  At the end of 12
weeks there was no statistically gross different in reduction of mean IOP in
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these three groups. All three groups significantly having reduction of IOP at the
end of 12 weeks.
IOP REDUCTION IN AETIOLOGIC GROUPS
Cause    Group I   Group II GroupIII
Pre
Treat-
ment
Post
Treat-
ment
Pre
Treat-
ment
Post
Treat-
ment
Pre
Treat-
ment
Post
Treat-
ment
PDR 38.83
±6.25
18.16
±6.78
44.62
±12.09
26.87
±11.82
6.05
±2.12
45
±2.82
CRVO 51.5
±7.77
41.5
±13.43
40
±2.82
24
±2.82
49.25
±20.85
29.55
±18.45
One way analysis of variance showed that the percentage of mean IOP
reduction in these three groups among various causes was not statistically
significant. This signifies that the cause does not influence the mean IOP
reduction in these three groups and neovascularisation and angle status
influence the outcome of treatment.
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POST OPERATIVE VISUAL STATUS
Group No change Improvement of
vision
Diminishion of
vision
I - - 10(100%)
II - 2(20%) 8(80%)
III 4(80%) - 1(20%)
Most of the patients had diminishion of vision post operatively. Only 2 patient
showed improvement of vision in Group II. This different modalities of
treatment concentrate to reduction in mean IOP not on the vision. Statistically
improvement of vision was not significant.
POST OPERATIVE COMPLICATION (GROUP I)
Complication Frequency Percentage
Uneventful 1 10%
Shallow AC 5 50%
Flat AC 1 10%
Blebitis 1 10%
Bleb leak 3 30%
Avascular bleb 1 10%
Bleb dyesthesia - 1
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1.Elevated bleb 30%
2.Cystic bleb 1
3.Overhanging bleb 1
Ocular hypotony 1 10%
Increased IOP 1 10%
Hyphaema 1 10%
Pain 3 30%
Dry eye 2 20%
FB sensation 2 20%
Blinking  problem 2 20%
Chemosis 1 10%
5( 50% ) patients had shallow anterior chamber. 8 (80%) patients had bleb
related complications like bleb leak (3),blebitis (1), avascular bleb (1), elevated
bleb (1), cystic bleb (1), overhanging bleb (1). One (10%) patient had ocular
hypotony. Ocular hypotony and shallow anterior chamber are most common
complication of Mitomycin –c. One (10%) patient had hyphaema24.  All  these
complications were effectively managed by appropriate treatment. Post
operative complications were more in this GroupI25 .
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POST OPERATIVE COMPLICATION( GROUP II)
Complication Frequency Percentage
Uneventful 6 60%
Pain 5 50%
Uveitis 2 20%
Increased IOP 2 20%
Chemosis 1 10%
Post operative complications were minimal in this group20. Only 2 patients
developed post operative mild iritis. This was controlled by topical medication.
Five patients had pain in immediate post operative period. This was relieved by
analgesic drugs.
POST OP COMPLICATION GROUP 1
UNEVENFUL
SHALLOW AC
FLAT AC
BLEBITIS
BLEB LEAK
AVASULAR BLEB
BLEB DYESTHESIA
OCULAR HYPOTONY
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POST OPERATIVE COMPLICATION ( GROUP III)
Complication Frequency Percentage
Uneventful 2 40%
Shallow AC 1 20%
Tube contact with cornea 1 20%
Uveitis 1 20%
Hyphaema 1 20%
Pain 4 80%
Shallow anterior chamber was found in 20% of patients in the early post
operative period. This reflects excessive drainage of aqueous or leak in anterior
chamber. This complication is more common in valve less drainage device26.
Reformation of  the anterior chamber was achieved with a pressure patch for a
longer time (10days).
POST OPERATIVE COMPLICATION GROUP 2
UNEVENTFUL
PAIN
UVEITIS
INCREASED IOP
CHEMOSIS
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Hyphaema is a well-recognized complication in surgery for neovascular
glaucoma. This is mainly due to intra operative bleeding. This was found in
20% of patients in early post operative period.
The cause of tube contact with cornea in one case was due to misdirection of the
tube. Proper scleral tunnelling will prevent this type of complication. One
patient had minimal post operative iritis. This was managed by topical
medication. Four patients had pain in immediate post operative period. This was
managed with analgesic drugs.
POST OP COMPLICATION GROUP 3
UNEVENTFUL
SHALLOW AC
TUBE CONTACT WITH CORNEA
UVEITIS
HYPHAEMA
PAIN
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SUMMARY
    This study was conducted in twenty five established cases of Neovascular
glaucoma between June 2011- June 2013.
    In all cases, detailed examination was done to find out the aetiology of
neovascular glaucoma and cases were followed up for a duration of 12 weeks.
    The mean age of presentation was 59.04 years with male preponderance
(Male: Female ratio 2.5:1)
   The patients were divided into five groups with respect toaetiology
proliferative diabetic retinopathy -12, CRVO -6, recrurrentarterior uveitis-2,
hypertension-1, others-4. Post traumatic, post surgical(cataract, retinal
detachment surgery)includes in others category. Proliferative diabetic
retinopathy was found to be major cause followed by CRVO and uveitis .
    The patients with CRVO presented earlier than the other groups.
   In this series of Neovascular glaucoma, the cases presented with anterior
segment features like oedema, bullous keratopathy,  keratic precipitates, iris
neovascularisation and posterior segment features like diabetic and hypertensive
retinopathy, CRVO, retinal detachment.
    Most of the patients had poor visual acuity ranging from PL to 1/60.
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     The mean IOP was 45.76 mmHg and majority of cases were in the range of
41- 50 mmHg.
     In this study 10 cases were subjected into Trabeculectomy with Mitomycin C
(Group I), 10 cases subjected into Trabeculectomy with Ologen implant ( Group
II), 5 cases were underwent Glaucoma drainage device surgery.
    There was no significant difference between the three treatment groups with
respect to vision, IOP, age, sex, aetiology and laterality of the eyes.
    There was a significant reduction in IOP between 3 groups in the follow up
period with mean reduction of 28.73, 26.3 and 26.38 in GroupI, GroupII and
Group III respectively. Maximum mean reduction of IOP in the first week seen
in group III(29.32 mean IOP reduction). At the end of 12 weeks of follow up
there was no statistically gross different in reduction of IOP between 3 groups.
    There was no statistically significant improvement of vision in any of the 3
groups.
    Post-operative complications more in group I (Trabeculectomy with
Mitomycin C) shallow anterior chamber was seen in 5 (50%) of the patients.
Flat anterior chamber was seen in 1 patient. Bleb related complications like bleb
leak (3), blebitis (1) bleb dyesthesia(3), cystic bleb1, overhanging bleb 1,
elevated bleb 1) due to the adverse effect of mitomycin drug. Ocular
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hypotonywas reported in 1 case. Pain , dry eye, foreign body sensation, blinking
problem, chemosis like problems also reported in groupI.
Post operative complication was minimal in group II. Only 2 patients were
developed  post operative minimal iritis.
    In group III, shallow anterior chamber (1), minimal iritis (1), hyphaema (1),
pain (4) present in immediate post operative period. Intra operative bleeding is
most common in Neovascular glaucoma patients. Tube contact with cornea
reported in 1 case. This may be due to misdirection of the tube while surgery.
60
CONCLUSION
Though  an  analysis  of  a  small  sample  of  twenty  five  cases  of  neovascular
glaucoma in this pilot study, the following could be concluded.
     The major aetiological factors causing Neovascular glaucoma are
proliferative diabetic retinopathy, central retinal vein occlusion, recurrent
anterior uveitis.
     The mean age of presentation was 59.04 years with male preponderance (
Male to Female ratio 2.5:1).
Neovascular glaucoma secondary to Central Retinal Vein Occlusion presented
earlier than proliferation diabetic retinopathy which was presented relatively
later.
       At most cases had corneal and iris involvement with new vessels extending
into the angle with or without synechial angle closure.
       The mean pre treatment intra ocular pressure was 45.76mmHg. among the
three modalities of treatment maximum mean reduction of IOP in the first week
was seen in group III (drainage implant surgery). But at the end of 12 weeks of
follow up all three groups showed statistically significant reduction of mean
IOP. There is no significant gross difference between these groups at the end of
12 weeks.
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      Group I -Trabeculectomy with Mitomycin - c showed more complication
compare to other 2 groups, shallow anterior chamber and bleb related
complications more common in group I.
Group II- Trabeculectomy with ologen implant showed minimal complications.
In Group III- drainage device surgery patients had complications like
hyphaema, tube contact with cornea and pain intra operative bleeding is more
common in neo vascular glaucoma patients.
       Patients with CRVO and uncontrolled diabetic patients came to the
ophthalmic surgeon or referred by a general practitioner only when the patient
develops painful eye with diabetic retinopathy. In this study 2 patients had PRP
in fellow eye. If PRP performed in affected eye previous itself means, they
rarely go for Neovascular glaucoma. Recurrent uveitis when treated properly
will rarely develop neovascular glaucoma. But these patients reported in this
study had inadequate treatment.
           If the patients would have presented earlier and managed appropriately,
this much dreaded complication of painful Neovascular glaucoma could be
avoided earlier.
          In severely compromised eyes with Neovascular glaucoma, the main
advantage of Keiki Metha Valve implantation is pain relief and avoidance of
enucleation in addition to a significant reduction in intra ocular pressure.
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CASE PROFORMA
SERIAL NO:                                DATE:                            OP/IP NO:
NAME:
AGE:
SEX:      MALE/FEMALE
ADDRESS:
PRESENTING COMPLAINTS:       ONSET              DURATION      RE/LE
     Defective vision
     Pain
     Redness
    Watering
H/O DM /HT /SIMILAR ATTACKS
PAST H/O:  previous attack
h/o suggestive of CRVO /CRAO/ TRAUMA
h/o surgery/ uveitis
TREATMENT H/O
h/o medications/  laser treatment
FAMILY H/O
                   Glaucoma, DM, HT
GENERAL EXAMINATION:
OCULAR EXAMINATION:                                 RE:                                 LE:
1. LIDS:
2. CONJUCTIVA: Congestion
Chemosis
Circumciliary congestion
3. CORNEA: Edema
Bullous keratopathy
Vascularisation
Thickening
Opacity
Keratic precipitates
Iris pigments
4. ANTERIOR CHAMBER:
Depth
Regular /irregular
Flare & cells
Hyphaema
Exudates
5. PUPILS: Reaction of light
Posterior synechiae
Ectropionuveae
Neovascularisation
Inflammatory membrane
Occlusio papillae
6. IRIS: Atrophic patches
Loss of pattern
Nodules
New vessels:
Extent - Pupillary  margin
- Mid stromal iris
- Iris base and angle
- Peripheral anterior synechiae
No of quadrants involved
- 1q,2q, 3q,4q
7. GONIOSCOPY : Angle – open /narrow/closed/new vessels/PAS
8. LENS: RE:                                  LE:
Cataract
Iris pigments
Phakia
Aphakia
Pseudo phakia
9. ANTERIOR FACE OF VITREOUS:     Cells/ strands
10. FUNDUS:   RE:  Media clarity                                        LE:
                             Hard exudates
                             Cotton wool spots
                             Vitreous hemorrhage
                             NVD
                             NVE             -sub hyaloid
                                                             -Vitreous
                                                             -Intra retinal
      11. TONOMETRY: RE:                                                        LE:
Shiotz
                                         NCT
Applanation
     12. VISUAL ACUITY:  RE with PH :                                     LE with PH:
     13. VISUAL FIELDS :  BJERRUM’S SCREEN          RE:                  LE:
          (possible cases)         AP
     14. INVESTIGATION:
                            BP
                            Urine - Albumin
                                         Sugar
                            Fasting and post prandial blood sugar
                            To R/o  uveitis
                                         Total count
                                         Differential count
                                         ESR
Mantoux
VDRL
B SCAN
Vitreous  hge/ RD/PVD
Indirect ophthalmoscopy
FFA  (if needed)
15. PROVISIONAL DIAGNOSIS:
16. DIAGNOSIS:
17. TREATMENT:
Trabeculectomy   with MMC
Trabeculectomy   with ologen
Drainage implant surgery
18. FOLLOW UP:
                           First week -   IOP/ Vn /post op complications(if any)
                           6th week –
                           12th week –
19. POST OP PERIOD:
Uneventful
Hyphaema
Flat AC
Tube contact with cornea
Hypotony
Supra choroidalhemorrhage
Rejection of implant
Pain
Chemosis
Uveitis
Increased IOP
Cataract
Avascular bleb
Bleb leak
Encysted bleb
Erotion of tube
Endophthalmitis
S.No. NAME AGE SEX
EYE
AFFECTED
DURATIO
N OF
ILLNESS
MOST
COMMON
SYMPTON
GENERAL
EXAMINA
TION
CORNEA AC PUPIL
PUPILLARY
REACTION
IRIS ANGLE
GRADE OF
NEO
VASOU
LARISATIO
N
LENS BP BLOOD
CAUSE OF
GLAU
COMA
STAGE OF
GLAU
COMA
MANAGE
MENT
POST-OP
COMPLIC
ATION
FELLOW
EYE
RE LE RE LE RE LE IOP VN IOP VN IOP VN
1 Bamavathy 55 F R c 1,2,3 2,4 2 2,8 4 4 2,3,5 2 B4 5b 2,4 2 36 20 HM 1/60 NIP 130/90 159 1 4 1 1,E 34 HM 26 PL 22 PL 4
2 Meenakshi 64 F R c 1 2 6 2 4,7 4 3,5 - - 5a 3 2,4 345 24
1/2 /60
NIP
6/60  with
PH 3/60 130/80 224 1 4 1 5,D 28 HM 24 HM 20 PL 6
3 Krishnaveni 65 F R b 1 1 2,8 1 3,4 5 5 2,4 C3 2b 2,6 2,6 59.1 42.1 NO PL HM 160/110 102 6 4 1 4B,7,A,C 29 HM 17.3 PL 17.3 PL 5,10
4 Jayalakshmi 60 F R a 1,2,3 1 2,8 3,5 3,4 4 5 3 C3 4 2 1 59.1 12 PL
6/24 with
PH 6/9 140/80 120 5 4 1 3,7,D 8 PL 8.5 NO PL 8.5 NO PL 3
5 Shamugam 60 M L a 1,2 1 5 1,5 3,4,7 3 5 3 D4 2b 5 2,5 16 46
6/12 with
PH 6/9 HM 140/90 106 2,6 4 1 3,7,D 10 PL 12 PL 14 PL 3,5
6 Sundarsanum 68 M L a 1 3 5 1 2,3,4,5 4 5 3,4,5 D4 2b 2,6 2,5,6 21.5 57 6/18 NIP 1/60 NIP 180/110 152 2,6 4 1 3,6,8 4 HM 6 NO PL 6 NO PL 5,6
7 Jayakumar 47 M R a 1 1 2,8 3 1,4 4 5 1 B4 5a 2 1 44 18 PL
6/24 with
PH 6/18 120/80 110 4 4 1 4C,4,B,C 24 NO PL 20 NO PL 22 NO PL 3
8 Munusamy 60 M L c 1 1 2 2 3,4,6 3 5,6 3 B4 2b 2 2 12.2 42.1 4/60 NIP PL 110/70 123 4 4 1 4a,7,A,C 10 NO PL 12 NO PL 10 NO PL 6
9 Mani 52 M R a 1,4,5 4 2,7 2 4,6 4 2,3,5 2 B4 2a 3 3 49.8 24.4 HM HM 130/80 164 3 4 1 2,7 34 PL 28 PL 30 PL 6
10 Srinivasan 65 M R c 2 2 2 1 4 3 5 3 C3 5a 2,4,6 2,6 46 12
6/60 with
PH 6/12
6/18 with
PH  6/9 130/90 182 1,6 4 1 16 26
4/60
with PH 12
4/60
with PH 20
5/60
with PH 3,4,5
11 John Staley 52 M L b 2 2 2,6 1,5 4 4 5 - - 2b 2,4 3 14.5 34.5
1/2 /60
NIP PL 120/80 124 1 4 2 16 22 PL 18 NO PL 18 NO PL 4,6
12 Jayakumar 56 M L c 1 2 2 1,5 4 4 5 3 B4 1 1,4 1,4 14.6 42.1
6/18 with
PH 6/12
4/60 with
PH 6/60 130/90 118 1 4 2 16D 18
1/2  /60
NIP 18 CFCF 14 CFCF 4
13 Rajendran 50 M R b 1 2 2 2 4 4 5 3,4 C3 2b 2,5 2 42 18 PL
6/12 with
PH 6/6 130/90 200 1 4 2 D,F,G 30 PL 34 PL 24 NO PL 6
14 Natrajan 67 M L a 1,2 3 5 2 4 3 2,5 2,4,5 D4 5a 2,7 2,4,6 12 38 PL
3/60 with
PH 6/60 140/100 0.102 2 4 2 16 20
3/60
with PH 14
3/60
with PH 12
3/60
with PH 2,9
15 Nagaboosanam 60 F R a 1 2,3 4,6 1 4 3 3,5 - - 2b 3 2 34 18
1/2 /60
NIP
6/12 with
PH 6/9 130/90 182 1 4 2 16 20
1/60
NIP 12 HM 14 HM 4,5,6
16 Sivakumar 55 M L b 1,2 2 2 1 3,4 3 5 1,4 C3 5a 2,4 2,4 14 49.1
6/18 with
PH 6/12 HM 110/70 116 1 4 2 D 32 HM 14 HM 14
1/2  /60
NIP 3,4
17 Chakkara 59 M R b 1 2,3 2 1 4 4 5 1,4 B4 2b 2,4 1,4 69.3 12.2 HM 6/60 P 120/80 302 1 4 2 D 38 HM 26 HM 18 CFCF 4
18 Ekambaram 63 M R b 1,5 1 2 1 3,4 3 2,3,5 1 B4 2a 3 2 42 12 PL
6/36 CPH
6/18 130/80 82 2 4 2 16,D,E 30 NO PL 21 NO PL 20 NO PL 6
19 Ponnusamy 56 M L b 1,2,5 1 2 1 4,7 3 5 3 C3 5a 2,4 2,4 12 52 3/60 NIP 3/60 NIP 130/90 302 1 4 2 F,G 34 CFCF 30 CFCF 24 CFCF 4
20 Rathinasamy 70 M L c 1 2,3 2 1 4 4 5 1 A4 2b 2,4 2,4 16 34
4/60 with
PH 6/18 CFCF 130/90 142 1 4 2 16 24 CFCF 20 CFCF 16
1/2  /60
NIP 4
21 Arokiasamy 60 M R b 1 1 2,7 4 2,4 4 5 1,4 C3 2b 2 2 42.5 12.4 CFCF
6/18 with
PH 6/9 110/70 102 3 4 3 16 12 CFCF 13.4 CFCF 17.3 CFCF 6
22 Kasthuri 62 F R c 1 2 3 1 2,4 4 3,5 - - 2b 3 2 61 17.3 HM 3/60 NIP 130/80 200 1 4 3 8,D 17 HM 12 HM 16 HM 4,6
23 Annam 55 F R a 1 1 2 1 3,4 4 3,5 3 C3 2b 2,5 2 64 17.3 PL 3/60 NIP 120/80 104 2 4 3 1,D 14 PL 17.3 PL 21.4 PL 6
24 Ramalingam 57 M R b 1 1 2 6 3,4 4 2,3,5 3 D3 2b 3 1 31.6 17.3 PL
6/18 with
PH 6/6 130/80 100 5 4 3 12,D,F 26 PL 29 PL 29 PL 6
25 Kalil Basha 58 M R a 1 3 2 1 3,4 4 5 3 C2 2b 2 2 34.5 12.2 PL
6/18 with
PH 6/12 120/80 335 1,2 4 3 16,D 18 PL 14 NO PL 18 NO PL 4,5
MASTER CHART
12 WKFUNDUS IOP VISION 1 WK 6wk
INDEX TO MASTER CHART
1. NAME
2. AGE
3. SEX – M- Male
 F- Female
4. Affected eye – Right –R
 Left – L
5. Duration of illness
a) 0-6 months
b) 7-12 months
c) >1 year
6. Most common systems
1. Defective vision
2. Pain
3. Redness
4. Watering
5. Others
7.General examination
         1. Normal
         2. DM
         3. HT
         4. Others
     8. Cornea
         1. Normal
         2. Edema
         3. Bullous keratopathy
         4. Vascularisation
         5. Stromal haze
         6. Opacity
         7. Keratic precipitates
         8. Iris pigments
9.Anterior chamber
1.Normal depth
2.Shallow
3.Deep
4.Irreguler
5.Flare and cells
6.Hypheama
7.Exudate
8.ACIOL
     10.Pupil
        1. Normal
        2. Posterior synechiae
        3. Ectropionuveae
        4. Neovascularisation
        5. Inflammatory membrane
        6. Occlusio papillae
        7. Irregular shape
    11. Pupillary reaction
1.Normal
2.Briskly acting
3.Sluggishly acting
4.Not acting
5.Relative afferent papillary defect
    12. Iris
1.Normal
2.Atrophic patches
3.Loss of pattern
4.Nodules
5.Neovascularisation
         6. Iris bombe
      14.Gonioscopy
          1. Open
          2. Narrow
          3. Closed
          4. New vessels
          5. PAS
          6. Membrane
          7. Others
     13.Grading of neovascularisation
         Extent
A. Pupillary margin
B. Mid stromal iris
C. Iris base and angle
D. PAS
1. 1 Quadrant
2.  2 Quadrant
3.  3 Quadrant
4.  4 Quadrant
       15.Lens
          1. Normal
2.Cataract a) Mature cataract
                            b) Immature cataract
          3. Iris pigments
          4. Aphakia
          5. Pseudophakia  a) PCIOL
                                       b) ACIOL
       16. Fundus RE- Right eye
                          LE-Left eye
1. Normal
2. Hazy view
3. No view
4. Diabetic retinopathy
5. Central retinal vein occlusion
6. Hypertensive retinopathy
7. Retinal detachment
8. Myopic fundus
9. Eales disease
10.Vitreoushemorrhage
       17. Intraocular pressure ( mmhg)
           RE-Right eye
           LE-Left eye
       18. Vision
           RE-Right eye
           LE-Left eye
       19. Blood pressure
       20. Blood sugar in mg %
       21. Cause of glaucoma
          1. Proliferative diabetic retinopathy
          2. Central retinal vein occlusion
          3. Recurrent anterior uveitis
          4. Post traumatic
          5. Post surgical
          6. Hypertension
          7. Others  a) Retinal detachment
                           b) Vitreous hemorrhage
                           c) Eales disease
                           d) Branch retinal vein occlusion
        22. Stage of glaucoma
           1. Early iris neovascularisation
           2. Moderate iris neovascularisation
           3. Advanced iris neovascularisation and angle involvement
           4. Neovascular glaucoma
        23. Management
           1. Trabeculectomy with Mitomycin –C
           2. Trabeculectomy with Ologen implant
           3. Drinage device implant surgery
        24. Post operative complication
           1. Hyphaema
           2. Avascular bleb
           3. Bleb leak
           4. Bleb dysesthesia   a) Cystic bleb
                                             b) Overhanging bleb
                                             c) Elevated bleb
           5. Blebitis
           6. Ocular hypotony
           7. Shallow anterior chamber
           8. Flat anterior chamber
           9. Cataract
           10. Hypotonusmaculopathy
           11. Choroidal detachment
           12. Tube contact with cornea
           13. Occlusion of tube
           14. Rejection of implant
           15. Endophthalmitis
           A) Blinking problem
           B) Dry eye
           C) Foreign body sensation
           D) Pain
           E) Chemosis
           F) Uveitis
          G) Increased IOP
          16.Uneventful
        25. First week
             IOP
             Visual acuity
        26. 6 week
             IOP
             Visual acuity
        27. 12 week
             IOP
             Visual acuity
        28. Fellow eye status
            1. Normal
            2. Aphakia
            3. Pseudophakia
            4. Diabetic retinopathy ( Fundus )
            5. Hypertensive retinopathy ( Fundus )
            6. Cataract
            7. Iridocyclitis
            8. Myopia
            9. Vascular occlusion
            10. Neovascular glaucoma
ABBREVIATIONS
CRVO – central retinal vein occlusion
FFA – fundus fluorescein angiography
IOP – intra ocular pressure
NVG – neo vascular glaucoma
PDR – proliferative diabetic retinopathy
PRP – pan retinal photo coagulation
SD –standard deviation
SE – standard error
